Mutations or amplification of many oncogenes, such as Ras and Myc, have been known for up to 40 years to be drivers of many different cancers. Yet, effective ways of targeting these for inhibition with small molecules still do not exist. Consequently, together with several other oncogenes, these are often referred to as ‘undruggable’ targets. Targeted degradation of such oncogenes has the potential to make them ‘druggable’ targets and potentially lead to therapeutics. Recently, several strategies have been developed to selectively target the degradation endogenous proteins.
Prof Paul Wyatt. Head of the Drug Discovery Unit, and Director of the Wellcome Centre for Anti-Infectives Research, University of Dundee is seeking a highly motivated and enthusiastic synthetic organic or medicinal chemist to carry out a PhD focused on developing innovative chemistry methodology to efficiently synthesise novel heterocycles as fragments. Fragments are low molecular weight and low complexity organic molecules suitable for initiating drug discovery projects.